{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T11:00:28Z","timestamp":1792839628784,"version":"4.5.0"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1796,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2010,10]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      <jats:bold>Colesevelam is an anion-exchange resin with a 7-fold higher bile acid\u2013binding capacity and fewer side effects than cholestyramine, the current first-line treatment option for cholestatic pruritus. The aim of this trial was to compare the effects of colesevelam and a placebo in patients with cholestatic pruritus. In a randomized, double-blind, investigator-initiated, multicenter trial, patients with cholestatic pruritus, both treatment-naive and previously treated, received 1875 mg of colesevelam or an identical placebo twice daily for 3 weeks. The effect on pruritus was assessed with daily visual analogue scales, quality-of-life scores, and evaluations of cutaneous scratch lesions. The predefined primary endpoint was the proportion of patients with at least a 40% reduction in pruritus visual analogue scale scores. Thirty-eight patients were included, and 35 were evaluable: 17 took colesevelam, 18 took the placebo, 22 were female, 8 were treatment-naive, 14 had primary biliary cirrhosis, and 14 had primary sclerosing cholangitis. The mean serum bile acid levels were comparable between the groups before treatment (<\/jats:bold>\n                      <jats:bold>P<\/jats:bold>\n                      <jats:bold>= 0.74), but they were significantly different after treatment (<\/jats:bold>\n                      <jats:bold>P<\/jats:bold>\n                      <jats:bold>= 0.01) in favor of patients treated with colesevelam. Thirty-six percent of patients in the colesevelam group reached the primary endpoint versus 35% in the placebo group (<\/jats:bold>\n                      <jats:bold>P<\/jats:bold>\n                      <jats:bold>= 1.0). There were no significant differences between the groups with respect to pruritus scores, quality-of-life scores, and severity of cutaneous scratch lesions. Mild side effects occurred in one colesevelam-treated patient and four placebo-treated patients.<\/jats:bold>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>\n                      <jats:bold>Although colesevelam significantly decreased serum bile acid levels, this trial was unable to demonstrate that it was more effective than a placebo in alleviating the severity of pruritus of cholestasis. (Hepatology 2010)<\/jats:bold>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/hep.23821","type":"journal-article","created":{"date-parts":[[2010,7,6]],"date-time":"2010-07-06T10:39:29Z","timestamp":1278412769000},"page":"1334-1340","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":115,"title":["The Potent Bile Acid Sequestrant Colesevelam Is Not Effective in Cholestatic Pruritus: Results of a Double-Blind, Randomized, Placebo-Controlled Trial"],"prefix":"10.1097","volume":"52","author":[{"given":"Edith M. M.","family":"Kuiper","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karel J.","family":"van Erpecum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Beuers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bettina E.","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing H.","family":"Thio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"de Man","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry L. A.","family":"Janssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henk R.","family":"van Buuren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20-20250312","doi-asserted-by":"crossref","first-page":"188189","DOI":"10.1126\/science.318.5848.188","article-title":"Biomedicine. Grasping for clues to the biology of itch.","volume":"318","author":"Miller","year":"2007","journal-title":"Science"},{"key":"R2-20-20250312","doi-asserted-by":"crossref","first-page":"21632182","DOI":"10.2165\/00003495-200868150-00006","article-title":"Pathogenesis and treatment of pruritus in cholestasis.","volume":"68","author":"Kremer","year":"2008","journal-title":"Drugs"},{"key":"R3-20-20250312","doi-asserted-by":"crossref","first-page":"857870","DOI":"10.1046\/j.1365-2036.2003.01458.x","article-title":"Review article: pruritus in cholestatic and other liver diseases.","volume":"17","author":"Mela","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"R4-20-20250312","first-page":"237267","article-title":"EASL clinical practice guidelines: management of cholestatic liver diseases.","volume":"51","year":"2009","journal-title":"J Hepatol"},{"key":"R5-20-20250312","doi-asserted-by":"crossref","first-page":"323332","DOI":"10.1016\/S0016-5085(66)80071-9","article-title":"Cholestyramine for long term relief of the pruritus complicating intrahepatic cholestasis.","volume":"50","author":"Datta","year":"1966","journal-title":"Gastroenterology"},{"key":"R6-20-20250312","first-page":"773776","article-title":"Doubleblind placebocontrolled clinical trial of microporous cholestyramine in the treatment of intra and extrahepatic cholestasis: relationship between itching and serum bile acids.","volume":"6","author":"Di Padova","year":"1984","journal-title":"Methods Find Exp Clin Pharmacol"},{"key":"R7-20-20250312","doi-asserted-by":"crossref","first-page":"488493","DOI":"10.1016\/0016-5085(88)90442-8","article-title":"Treatment of pruritus in primary biliary cirrhosis with rifampin. Results of a doubleblind, crossover, randomized trial.","volume":"94","author":"Ghent","year":"1988","journal-title":"Gastroenterology"},{"key":"R8-20-20250312","doi-asserted-by":"crossref","first-page":"216220","DOI":"10.1007\/BF01300759","article-title":"Treatment of pruritus of primary biliary cirrhosis with rifampin.","volume":"36","author":"Podesta","year":"1991","journal-title":"Dig Dis Sci"},{"key":"R9-20-20250312","doi-asserted-by":"crossref","first-page":"544549","DOI":"10.1016\/0016-5085(92)90102-5","article-title":"A controlled trial of naloxone infusions for the pruritus of chronic cholestasis.","volume":"102","author":"Bergasa","year":"1992","journal-title":"Gastroenterology"},{"key":"R10-20-20250312","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1053\/gast.1997.v113.pm9322521","article-title":"Oral naltrexone treatment for cholestatic pruritus: a doubleblind, placebocontrolled study.","volume":"113","author":"Wolfhagen","year":"1997","journal-title":"Gastroenterology"},{"key":"R11-20-20250312","doi-asserted-by":"crossref","first-page":"666674","DOI":"10.1002\/hep.21553","article-title":"Sertraline as a firstline treatment for cholestatic pruritus.","volume":"45","author":"Mayo","year":"2007","journal-title":"Hepatology"},{"key":"R12-20-20250312","doi-asserted-by":"crossref","first-page":"971982","DOI":"10.4065\/76.10.971","article-title":"Effectiveness of colesevelam hydrochloride in decreasing LDL cholesterol in patients with primary hypercholesterolemia: a 24week randomized controlled trial.","volume":"76","author":"Insull","year":"2001","journal-title":"Mayo Clin Proc"},{"key":"R13-20-20250312","doi-asserted-by":"crossref","first-page":"932939","DOI":"10.1093\/ajhp\/59.10.932","article-title":"Colesevelam hydrochloride.","volume":"59","author":"Steinmetz","year":"2002","journal-title":"Am J Health Syst Pharm"},{"key":"R14-20-20250312","doi-asserted-by":"crossref","first-page":"18931900","DOI":"10.1001\/archinte.159.16.1893","article-title":"Colesevelam hydrochloride (Cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects.","volume":"159","author":"Davidson","year":"1999","journal-title":"Arch Intern Med"},{"key":"R15-20-20250312","first-page":"541A","article-title":"Use of colesevelam hydrochloride (Welchol) as a novel therapeutic agent for the management of refractory pruritus in chronic liver disease Abstract.","volume":"34","author":"Berg","year":"2001","journal-title":"Hepatology"},{"key":"R16-20-20250312","doi-asserted-by":"crossref","first-page":"A3006","DOI":"10.1136\/bmj.a3006","article-title":"Reporting and interpretation of SF36 outcomes in randomised trials: systematic review.","volume":"338","author":"ContopoulosIoannidis","year":"2009","journal-title":"BMJ"},{"key":"R17-20-20250312","first-page":"14691481","article-title":"The Liver Disease Symptom Index 2.0; validation of a diseasespecific questionnaire.","volume":"13","author":"van der Plas","year":"2004","journal-title":"Qual Life Res"},{"key":"R18-20-20250312","doi-asserted-by":"crossref","first-page":"280281","DOI":"10.1002\/hep.21271","article-title":"Biliary drainage transiently relieves intractable pruritus in primary biliary cirrhosis.","volume":"44","author":"Beuers","year":"2006","journal-title":"Hepatology"},{"key":"R19-20-20250312","doi-asserted-by":"crossref","first-page":"5153","DOI":"10.1002\/hep.20998","article-title":"Nasobiliary drainage induces longlasting remission in benign recurrent intrahepatic cholestasis.","volume":"43","author":"Stapelbroek","year":"2006","journal-title":"Hepatology"},{"key":"R20-20-20250312","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1136\/bmj.289.6436.22","article-title":"Treatment of pruritus due to chronic obstructive liver disease.","volume":"289","author":"Duncan","year":"1984","journal-title":"Br Med J (Clin Res Ed)"},{"key":"R21-20-20250312","doi-asserted-by":"crossref","first-page":"15281536","DOI":"10.1111\/j.1572-0241.2007.01200.x","article-title":"The efficacy and safety of bile acid binding agents, opioid antagonists, or rifampin in the treatment of cholestasisassociated pruritus.","volume":"102","author":"Tandon","year":"2007","journal-title":"Am J Gastroenterol"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.23821","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-201010000-00020","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T07:09:06Z","timestamp":1741763346000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-201010000-00020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.23821","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.7416957.7698055","asserted-by":"object"}]},"ISSN":["0270-9139"],"issn-type":[{"value":"0270-9139","type":"print"}],"subject":[],"published":{"date-parts":[[2010,10]]}}}